<DOC>
	<DOCNO>NCT00994916</DOCNO>
	<brief_summary>The purpose study provide expand access ( compassionate use ) 3,4 diaminopyridine patient Lambert-Eaton myasthenic syndrome ( LEMS ) .</brief_summary>
	<brief_title>Treatment Lambert-Eaton Syndrome With 3,4 Diaminopyridine</brief_title>
	<detailed_description>Up 15 patient age 18 year diagnosis LEMS eligible enroll medically stable . They may receive 3,4 diaminopyridine addition treatment standard care investigation LEMS supervision primary investigator . Safety laboratory study EKGs obtain . The study approve University Pittsburgh IRB . There local Data-Safety Monitoring Board .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>1 . Diagnosis LEMS 2 . Over 18 year old 3 . Medically stable 4 . If female premenopausal , negative urine pregnancy test prior start 3,4 DAP , , premenopausal , willing practice effective form birth control `` doublebarrier contraception '' study 1 . Known sensitivity 3,4 DAP 2 . History past current seizure 3 . History severe asthma 4 . Believed investigator unable comply protocol 5 . Unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Lambert-Eaton myasthenic syndrome</keyword>
	<keyword>3,4 diaminopyridine</keyword>
</DOC>